| Literature DB >> 30936025 |
V Lavoue1, C Huchon2, C Akladios3, P Alfonsi4, N Bakrin5, M Ballester6, S Bendifallah7, P A Bolze8, F Bonnet9, C Bourgin10, N Chabbert-Buffet7, P Collinet10, B Courbiere11, T De la Motte Rouge12, M Devouassoux-Shisheboran13, C Falandry14, G Ferron15, L Fournier16, L Gladieff17, F Golfier8, S Gouy18, F Guyon19, E Lambaudie20, A Leary21, F Lecuru22, M A Lefrere-Belda23, E Leblanc24, A Lemoine9, F Narducci24, L Ouldamer25, P Pautier21, F Planchamp26, N Pouget27, I Ray-Coquard28, C Rousset-Jablonski28, C Senechal-Davin19, C Touboul29, I Thomassin-Naggara30, C Uzan31, B You32, E Daraï7.
Abstract
Adjuvant chemotherapy by carboplatin and paclitaxel is recommended for all high-grade ovarian and tubal cancers (FIGO stages I-IIA) (grade A). After primary surgery is complete, 6 cycles of intravenous chemotherapy (grade A) are recommended, or a discussion with the patient about intraperitoneal chemotherapy, according to her risk-benefit ratio. After complete interval surgery for FIGO stage III, hyperthermic intraperitoneal chemotherapy (HIPEC) can be proposed, in accordance with the modalities of the OV-HIPEC trial (grade B). In cases of postoperative tumor residue or in FIGO stage IV tumors, chemotherapy associated with bevacizumab is recommended (grade A).Entities:
Keywords: Chemotherapy; Guidelines; Ovarian cancer; Primary peritoneal cancer; Surgery; Tubal cancer
Mesh:
Substances:
Year: 2019 PMID: 30936025 DOI: 10.1016/j.jogoh.2019.03.018
Source DB: PubMed Journal: J Gynecol Obstet Hum Reprod ISSN: 2468-7847